Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· November 30, 2025

The Many Reasons to Roth

View original at nasdaq.com
The Many Reasons to Roth In this podcast, Motley Fool retirement experts Robert Brokamp and Dan Caplinger discuss five reasons why you might want to go with the Roth…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The ratio of household wealth to income is at an all time high

    80% confidence
  • The years before required minimum distributions kick in, but after you have decided to retire, sometimes that's the best time to consider a Roth conversion

    80% confidence
  • A reasonable default option for retirement plan is living to age 95, since there's a 20-25% chance that one member of a 65-year-old couple will live to their mid 90s

    80% confidence
  • When you have money in a traditional account, you basically have a co-owner of the account, the co-owner being Uncle Sam

    80% confidence
  • For a lot of folks, including a lot of Motley Fool members, those later tax rates can be higher than what you're paying now, especially if you're early in your career not paying much in taxes yet

    80% confidence
  • Household net worth is now more than eight times after tax income compared with an average of 5.5 times after tax income in the decades between World War II and the great financial crisis of 2008

    80% confidence
  • The top 10% own 87% of all equities and mutual funds

    80% confidence
  • Little by little, sometimes is the best way to get these things done with Roth conversions

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com